New indication Di-Adreson®-F aquosum 25 mg

08 September 2014

Since 7th July 2014 is Di-Adreson-F aquosum 25 mg (DAF) also licensed for Acute Lymphatic Leukemia (ALL) in children and adolescents by intrathecal administration.

For this indication is DAF the only licensed corticosteroid (ALL-11) that does not contain preservatives, complex formers (EDTA) or buffers.

DAF can be used safely, via all usual routes of administration, in every situation where a corticosteroid by injection is the indicated treatment.

In ALL, DAF is administered intrathecal in combination with other medicines as indicated in the SKION-protocol (Methotrexate and Cytarabine).